{"paper_id":"9cbccf53-a4e5-4ba6-9d16-79d3087ba73c","body_text":"Abstract\nEndometriosis is a multifaceted chronic disease with a complex and variable display of clinical symptoms. Chronic pelvic pain (CPP) affects most women with endometriosis, leaving patients frequently suffering from widespread pain, often associated with painful comorbidities. Despite this significant disease burden, limited progress has been made in elucidating the mechanisms contributing to endometriosis-associated CPP development. Accordingly, therapies that adequately target and treat the debilitating pain remain lacking. Small animal models of endometriosis show considerable promise as pre-clinical tools to investigate the mechanisms of CPP; however, the majority of these studies focus on the pathogenesis and development of endometriosis, which leaves the mechanisms underlying CPP elusive. When established behavioural techniques are incorporated into these pre-clinical animal models of endometriosis, it is apparent that they recapitulate key pain attributes that are observed clinically in women with endometriosis. However, studies often employ only one or two behavioural techniques focused on an individual symptom, rather than utilising multiple techniques to uncover the mechanisms underlying diverse and comorbid pain. As many women with endometriosis suffer from widespread pain that frequently affecting multiple organs, a paradigm shift aimed at encompassing a multifaceted approach is essential for the future study of endometriosis-associated pain.\nAccess this chapter\nTax calculation will be finalised at checkout\nPurchases are for personal use only\nSimilar content being viewed by others\nAbbreviations\n- CD3:\n-\nCluster of differentiation 3\n- CPP:\n-\nChronic pelvic pain\n- HLA-DR:\n-\nHuman leukocyte antigen – DR isotope\n- IBD:\n-\nInflammatory bowel disease\n- IBS:\n-\nIrritable bowel syndrome\n- IC/BPS:\n-\nInterstitial cystitis/bladder pain syndrome\n- TGFβ:\n-\nTransforming growth factor β\n- TNFα:\n-\nTumour necrosis factor\n- VEGF:\n-\nVascular endothelial growth factor\nReferences\nAdamson G, Kennedy S, Hummelshoj L. Creating solutions in endometriosis: Global collaboration through the World Endometriosis Research Foundation; 2010. 3–6 p.\nAlali Z, Graham A, Swan K, Flyckt R, Falcone T, Cui W, et al. 60S acidic ribosomal protein P1 (RPLP1) is elevated in human endometriotic tissue and in a murine model of endometriosis and is essential for endometriotic epithelial cell survival in vitro. Mol Hum Reprod. 2020;26(1):53–64.\nAlvarez P, Bogen O, Levine JD. Role of nociceptor estrogen receptor GPR30 in a rat model of endometriosis pain. Pain. 2014;155(12):2680–6.\nAnaf V, Simon P, El Nakadi I, Fayt I, Buxant F, Simonart T, et al. Relationship between endometriotic foci and nerves in rectovaginal endometriotic nodules. Hum Reprod. 2000;15(8):1744–50.\nArruda MS, Petta CA, Abrao MS, Benetti-Pinto CL. Time elapsed from onset of symptoms to diagnosis of endometriosis in a cohort study of Brazilian women. Hum Reprod. 2003;18(4):756–9.\nBallard KD, Seaman HE, de Vries CS, Wright JT. Can symptomatology help in the diagnosis of endometriosis? Findings from a national case-control study--Part 1. BJOG. 2008;115(11):1382–91.\nBecker CM, Rohwer N, Funakoshi T, Cramer T, Bernhardt W, Birsner A, et al. 2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis. Am J Pathol. 2008;172(2):534–44.\nBirt JA, Taylor KH, Davis JW, Sharpe-Timms KL. Developmental exposure of fetal ovaries and fetal germ cells to endometriosis in an endometriosis model causes differential gene expression in the preimplantation embryos of the first-generation and second-generation embryos. Fertil Steril. 2013;100(5):1436–43.\nBraundmeier AG, Fazleabas AT. The non-human primate model of endometriosis: research and implications for fecundity. Mol Hum Reprod. 2009;15(10):577–86.\nCastro J, Maddern J, Grundy L, Manavis J, Harrington AM, Schober G, et al. A mouse model of endometriosis that displays vaginal, colon, cutaneous, and bladder sensory comorbidities. FASEB J. 2021;35(4):e21430.\nChen Z, Xie F, Bao M, Li X, Chao Y, Lin C, et al. Activation of p38 MAPK in the rostral ventromedial medulla by visceral noxious inputs transmitted via the dorsal columns may contribute to pelvic organ cross-sensitization in rats with endometriosis. Neuroscience. 2015;291:272–8.\nChung MK, Chung RP, Gordon D. Interstitial cystitis and endometriosis in patients with chronic pelvic pain: the “Evil Twins” syndrome. JSLS. 2005;9(1):25–9.\nD’Hooghe TM, Bambra CS, Xiao L, Peixe K, Hill JA. Effect of menstruation and intrapelvic injection of endometrium on inflammatory parameters of peritoneal fluid in the baboon (Papio anubis and Papio cynocephalus). Am J Obstet Gynecol. 2001;184(5):917–25.\nD’Hooghe TM, Kyama CM, Chai D, Fassbender A, Vodolazkaia A, Bokor A, et al. Nonhuman primate models for translational research in endometriosis. Reprod Sci. 2009;16(2):152–61.\nDick EJ Jr, Hubbard GB, Martin LJ, Leland MM. Record review of baboons with histologically confirmed endometriosis in a large established colony. J Med Primatol. 2003;32(1):39–47.\nDmitrieva N, Faircloth E, Pyatok S, Sacher F, Patchev V. Telemetric assessment of referred vaginal hyperalgesia and the effect of indomethacin in a rat model of endometriosis. Front Pharmacol. 2012;3:158.\nDorning A, Dhami P, Panir K, Hogg C, Park E, Ferguson GD, et al. Bioluminescent imaging in induced mouse models of endometriosis reveals differences in four model variations. Dis Model Mech. 2021;14(8):dmm049070.\nEscudero-Lara A, Argerich J, Cabañero D, Maldonado R. Disease-modifying effects of natural Δ9-tetrahydrocannabinol in endometriosis-associated pain. elife. 2020;9:e50356.\nEscudero-Lara A, Cabañero D, Maldonado R. Kappa opioid receptor modulation of endometriosis pain in mice. Neuropharmacology. 2021;195:108677.\nFattori V, Franklin NS, Gonzalez-Cano R, Peterse D, Ghalali A, Madrian E, et al. Nonsurgical mouse model of endometriosis-associated pain that responds to clinically active drugs. Pain. 2020;161(6):1321–31.\nForster R, Sarginson A, Velichkova A, Hogg C, Dorning A, Horne AW, et al. Macrophage-derived insulin-like growth factor-1 is a key neurotrophic and nerve-sensitizing factor in pain associated with endometriosis. FASEB J. 2019;33(10):11210–22.\nGashaw I, Hastings JM, Jackson KS, Winterhager E, Fazleabas AT. Induced endometriosis in the baboon (Papio anubis) increases the expression of the proangiogenic factor CYR61 (CCN1) in eutopic and ectopic endometria. Biol Reprod. 2006;74(6):1060–6.\nGe P, Ren J, Harrington AM, Grundy L, Castro J, Brierley SM, et al. Linaclotide treatment reduces endometriosis-associated vaginal hyperalgesia and mechanical allodynia through viscerovisceral cross-talk. Pain. 2019;160:2566.\nGreaves E, Cousins FL, Murray A, Esnal-Zufiaurre A, Fassbender A, Horne AW, et al. A novel mouse model of endometriosis mimics human phenotype and reveals insights into the inflammatory contribution of shed endometrium. Am J Pathol. 2014a;184(7):1930–9.\nGreaves E, Collins F, Esnal-Zufiaurre A, Giakoumelou S, Horne AW, Saunders PT. Estrogen receptor (ER) agonists differentially regulate neuroangiogenesis in peritoneal endometriosis via the repellent factor SLIT3. Endocrinology. 2014b;155(10):4015–26.\nGreaves E, Critchley HOD, Horne AW, Saunders PTK. Relevant human tissue resources and laboratory models for use in endometriosis research. Acta Obstet Gynecol Scand. 2017a;96(6):644–58.\nGreaves E, Horne AW, Jerina H, Mikolajczak M, Hilferty L, Mitchell R, et al. EP(2) receptor antagonism reduces peripheral and central hyperalgesia in a preclinical mouse model of endometriosis. Sci Rep. 2017b;7:44169.\nGreaves E, Rosser M, Saunders PTK. Endometriosis-associated pain – do preclinical rodent models provide a good platform for translation? In: Sharpe-Timms KL, editor. Animal models for endometriosis: evolution, utility and clinical relevance. Cham: Springer International Publishing; 2020. p. 25–55.\nGrundy L, Harrington AM, Castro J, Garcia-Caraballo S, Deiteren A, Maddern J, et al. Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction. JCI Insight. 2018;3(19):e121841.\nGuo SW. Recurrence of endometriosis and its control. Hum Reprod Update. 2009;15(4):441–61.\nHadfield R, Mardon H, Barlow D, Kennedy S. Delay in the diagnosis of endometriosis: a survey of women from the USA and the UK. Hum Reprod. 1996;11(4):878–80.\nHill WG, Zeidel ML, Bjorling DE, Vezina CM. Void spot assay: recommendations on the use of a simple micturition assay for mice. Am J Physiol-Renal Physiol. 2018;315(5):F1422–F9.\nHorne AW, Ahmad SF, Carter R, Simitsidellis I, Greaves E, Hogg C, et al. Repurposing dichloroacetate for the treatment of women with endometriosis. Proc Natl Acad Sci U S A. 2019a;116(51):25389–91.\nHorne AW, Daniels J, Hummelshoj L, Cox E, Cooper KG. Surgical removal of superficial peritoneal endometriosis for managing women with chronic pelvic pain: time for a rethink? BJOG. 2019b;126(12):1414–6.\nHoward FM. An evidence-based medicine approach to the treatment of endometriosis-associated chronic pelvic pain: placebo-controlled studies. J Am Assoc Gynecol Laparosc. 2000;7(4):477–88.\nHull ML, Charnock-Jones DS, Chan CL, Bruner-Tran KL, Osteen KG, Tom BD, et al. Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab. 2003;88(6):2889–99.\nHull ML, Johan MZ, Hodge WL, Robertson SA, Ingman WV. Host-derived TGFB1 deficiency suppresses lesion development in a mouse model of endometriosis. Am J Pathol. 2012;180(3):880–7.\nHusby GK, Haugen RS, Moen MH. Diagnostic delay in women with pain and endometriosis. Acta Obstet Gynecol Scand. 2003;82(7):649–53.\nIngelmo JMR, Quereda F, Acién P. Intraperitoneal and subcutaneous treatment of experimental endometriosis with recombinant human interferon-α-2b in a murine model. Fertil Steril. 1999;71(5):907–11.\nJess T, Frisch M, Jorgensen KT, Pedersen BV, Nielsen NM. Increased risk of inflammatory bowel disease in women with endometriosis: a nationwide Danish cohort study. Gut. 2012;61(9):1279–83.\nKhan KN, Kitajima M, Fujishita A, Hiraki K, Matsumoto A, Nakashima M, et al. Pelvic pain in women with ovarian endometrioma is mostly associated with coexisting peritoneal lesions. Hum Reprod. 2013;28(1):109–18.\nLangoi D, Pavone ME, Gurates B, Chai D, Fazleabas A, Bulun SE. Aromatase inhibitor treatment limits progression of peritoneal endometriosis in baboons. Fertil Steril. 2013;99(3):656–62.e3.\nLi T, Mamillapalli R, Ding S, Chang H, Liu ZW, Gao XB, et al. Endometriosis alters brain electrophysiology, gene expression and increases pain sensitization, anxiety, and depression in female mice. Biol Reprod. 2018;99(2):349–59.\nLiu M, Liu X, Zhang Y, Guo SW. Valproic acid and progestin inhibit lesion growth and reduce hyperalgesia in experimentally induced endometriosis in rats. Reprod Sci. 2012;19(4):360–73.\nLiu Z, Chen S, Qiu C, Sun Y, Li W, Jiang J, et al. Fractalkine/CX3CR1 contributes to endometriosis-induced neuropathic pain and mechanical hypersensitivity in rats. Front Cell Neurosci. 2018;12:495.\nMaddern J, Grundy L, Castro J, Brierley SM. Pain in endometriosis. Front Cell Neurosci. 2020;14(335):590823.\nMaddern J, Grundy L, Harrington A, Schober G, Castro J, Brierley SM. A syngeneic inoculation mouse model of endometriosis that develops multiple comorbid visceral and cutaneous pain like behaviours. Pain. 2022;163(8):1622.\nMalvezzi H, Marengo EB, Podgaec S, Piccinato CA. Endometriosis: current challenges in modeling a multifactorial disease of unknown etiology. J Transl Med. 2020;18(1):311.\nMcAllister SL, McGinty KA, Resuehr D, Berkley KJ. Endometriosis-induced vaginal hyperalgesia in the rat: role of the ectopic growths and their innervation. Pain. 2009;147(1–3):255–64.\nMcAllister SL, Dmitrieva N, Berkley KJ. Sprouted innervation into uterine transplants contributes to the development of hyperalgesia in a rat model of endometriosis. PLoS One. 2012;7(2):e31758.\nMcKinnon B, Bersinger NA, Wotzkow C, Mueller MD. Endometriosis-associated nerve fibers, peritoneal fluid cytokine concentrations, and pain in endometriotic lesions from different locations. Fertil Steril. 2012;97(2):373–80.\nMogil JS. Animal models of pain: progress and challenges. Nat Rev Neurosci. 2009;10(4):283–94.\nMogil JS, Crager SE. What should we be measuring in behavioral studies of chronic pain in animals? Pain. 2004;112(1–2):12–5.\nNagabukuro H, Berkley KJ. Influence of endometriosis on visceromotor and cardiovascular responses induced by vaginal distention in the rat. Pain. 2007;132(Suppl 1):S96–103.\nNnoaham KE, Hummelshoj L, Webster P, d’Hooghe T, de Cicco Nardone F, de Cicco Nardone C, et al. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertil Steril. 2011;96(2):366–73 e8.\nNothnick WB, Colvin A, Cheng KF, Al-Abed Y. Inhibition of macrophage migration inhibitory factor reduces endometriotic implant size in mice with experimentally induced disease. J Endometr. 2011;3(3):135–42.\nNunez-Badinez P, De Leo B, Laux-Biehlmann A, Hoffmann A, Zollner TM, Saunders PTK, et al. Preclinical models of endometriosis and interstitial cystitis/bladder pain syndrome: an Innovative Medicines Initiative-PainCare initiative to improve their value for translational research in pelvic pain. Pain. 2021;162(9):2349–65.\nPelch KE, Schroder AL, Kimball PA, Sharpe-Timms KL, Davis JW, Nagel SC. Aberrant gene expression profile in a mouse model of endometriosis mirrors that observed in women. Fertil Steril. 2010;93(5):1615–27. e18\nPelch KE, Sharpe-Timms KL, Nagel SC. Mouse model of surgically-induced endometriosis by auto-transplantation of uterine tissue. J Vis Exp. 2012;59:e3396.\nQuereda F, Bermejo R, Velasco I, Campos A, Acién P. The effect of intraperitoneal interleukin-2 on surgically induced endometriosis in rats. Eur J Obstet Gynecol Reprod Biol. 2008;136(2):243–8.\nRogers PAW, Adamson GD, Al-Jefout M, Becker CM, D’Hooghe TM, Dunselman GAJ, et al. Research priorities for endometriosis. Reprod Sci (Thousand Oaks, Calif). 2017;24(2):202–26.\nSaunders PTK. What have we learned from animal models of endometriosis and how can we use the knowledge gained to improve treatment of patients? In: Sharpe-Timms KL, editor. Animal models for endometriosis: evolution, utility and clinical relevance. Cham: Springer International Publishing; 2020. p. 99–111.\nSchomacker ML, Hansen KE, Ramlau-Hansen CH, Forman A. Is endometriosis associated with irritable bowel syndrome? A cross-sectional study. Eur J Obstet Gynecol Reprod Biol. 2018;231:65–9.\nSharpe K, Bertero M, Vernon M. Rapid regression of endometriosis by a new gonadotropin-releasing hormone antagonist in rats with surgically induced disease. Prog Clin Biol Res. 1990;323:449–58.\nSharpe KL, Bertero MC, Muse KN, Vernon MW. Spontaneous and steroid-induced recurrence of endometriosis after suppression by a gonadotropin-releasing hormone antagonist in the rat. Am J Obstet Gynecol. 1991;164(1, Part 1):187–94.\nSignorile PG, Cassano M, Viceconte R, Marcattilj V, Baldi A. Endometriosis: a retrospective analysis of clinical data from a cohort of 4,083 patients, with focus on symptoms. In Vivo. 2022;36(2):874–83.\nSimoens S, Hummelshoj L, D’Hooghe T. Endometriosis: cost estimates and methodological perspective. Hum Reprod Update. 2007;13(4):395–404.\nStilley JAW, Woods-Marshall R, Sutovsky M, Sutovsky P, Sharpe-Timms KL. Reduced fecundity in female rats with surgically induced endometriosis and in their daughters: a potential role for tissue inhibitors of metalloproteinase 1. Biol Reprod. 2009;80(4):649–56.\nStilley JAW, Birt JA, Nagel SC, Sutovsky M, Sutovsky P, Sharpe-Timms KL. Neutralizing TIMP1 restores fecundity in a rat model of endometriosis and treating control rats with TIMP1 causes anomalies in ovarian function and embryo development. Biol Reprod. 2010;83(2):185–94.\nSurrey ES, Soliman AM, Castelli-Haley J, Snabes MC, Johnson SJ, Davis M. Risk of developing comorbidities among women with endometriosis: a retrospective matched cohort study. J Women’s Health (15409996). 2018;27(9):1114–23.\nTappe-Theodor A, Kuner R. Studying ongoing and spontaneous pain in rodents – challenges and opportunities. Eur J Neurosci. 2014;39(11):1881–90.\nTejada MA, Santos-Llamas AI, Escriva L, Tarin JJ, Cano A, Fernández-Ramírez MJ, et al. Identification of altered evoked and non-evoked responses in a heterologous mouse model of endometriosis-associated pain. Biomedicine. 2022;10(2):501.\nTirlapur SA, Kuhrt K, Chaliha C, Ball E, Meads C, Khan KS. The ‘evil twin syndrome’ in chronic pelvic pain: a systematic review of prevalence studies of bladder pain syndrome and endometriosis. Int J Surg. 2013;11(3):233–7.\nVernon MW, Wilson EA. Studies on the surgical induction of endometriosis in the rat. Fertil Steril. 1985;44(5):684–94.\nXu H, Becker CM, Lui WT, Chu CY, Davis TN, Kung AL, et al. Green tea epigallocatechin-3-gallate inhibits angiogenesis and suppresses vascular endothelial growth factor C/vascular endothelial growth factor receptor 2 expression and signaling in experimental endometriosis in vivo. Fertil Steril. 2011;96(4):1021–8.\nZheng Y, Liu X, Guo SW. Therapeutic potential of andrographolide for treating endometriosis. Hum Reprod. 2012;27(5):1300–13.\nZondervan KT, Becker CM, Missmer SA. Endometriosis. N Engl J Med. 2020;382(13):1244–56.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nEditor information\nEditors and Affiliations\nRights and permissions\nCopyright information\n© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG\nAbout this chapter\nCite this chapter\nMaddern, J., Brierley, S.M., Castro, J. (2023). Pre-clinical Models of Endometriosis: A Focus on Chronic Pain. In: Brierley, S.M., Spencer, N.J. (eds) Visceral Pain. Springer, Cham. https://doi.org/10.1007/978-3-031-25702-5_16\nDownload citation\nDOI: https://doi.org/10.1007/978-3-031-25702-5_16\nPublished:\nPublisher Name: Springer, Cham\nPrint ISBN: 978-3-031-25701-8\nOnline ISBN: 978-3-031-25702-5\neBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)","source_license":"CC0","license_restricted":false}